NCT03735121 · OUTCOME

Part 2: Overall Survival (OS)

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Source last updated 2025-12-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Up to approximately 44.7 months

What was measured

OS was defined as the time from the date of study randomization to the date of death from any cause.

Analysis population: FAS included all randomized participants, with participants grouped according to their assigned treatment.

Groups in this outcome

Part 2: Atezolizumab IV 1200 mg

Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.

Part 2: Atezolizumab SC 1875 mg

Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	124
Part 2: Atezolizumab SC 1875 mg	247

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	10.1	Not reported	7.5	12.3	Not reported
Part 2: Atezolizumab SC 1875 mg	10.9	Not reported	8.5	14.4	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
0.78
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.27
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.9766
param Type
Hazard Ratio (HR)
param Value
1.00
statistical Method
Log Rank

Complete source fields

analyses

ci Lower Limit
0.78
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.27
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
p Value
0.9766
param Type
Hazard Ratio (HR)
param Value
1.00
statistical Method
Log Rank

classes

categories
measurements
group Id
OG000
lower Limit
7.5
upper Limit
12.3
value
10.1
group Id
OG001
lower Limit
8.5
upper Limit
14.4
value
10.9

denoms

counts
group Id
OG000
value
124
group Id
OG001
value
247
units
Participants

description

OS was defined as the time from the date of study randomization to the date of death from any cause.

dispersion Type

95% Confidence Interval

groups

description
Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
id
OG000
title
Part 2: Atezolizumab IV 1200 mg
description
Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
id
OG001
title
Part 2: Atezolizumab SC 1875 mg

param Type

MEDIAN

population Description

FAS included all randomized participants, with participants grouped according to their assigned treatment.

reporting Status

POSTED

time Frame

Up to approximately 44.7 months

title

Part 2: Overall Survival (OS)

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice